Inhibition of androgen receptor and β-catenin activity in prostate cancer - Wikidata - wikimedia - TriplyDB

Inhibition of androgen receptor and β-catenin activity in prostate cancer

Inhibition of androgen receptor and β-catenin activity in prostate cancer

http://www.wikidata.org/entity/Q34982553

about

Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer Novel cancer chemotherapy hits by molecular topology: dual Akt and Beta-catenin inhibitors Wnt some lose some: transcriptional governance of stem cells by Wnt/β-catenin signaling.Molecular pathways and targets in prostate cancer Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.The biology of castration-resistant prostate cancer Androgen receptor in hepatocarcinogenesis: Recent developments and perspectives.Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells.Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma.Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer Integrated network model provides new insights into castration-resistant prostate cancer ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.Wnt signaling in castration-resistant prostate cancer: implications for therapy.Prostate cancer stem cells: from theory to practice.SOX9 drives WNT pathway activation in prostate cancer.Revisiting the role of Wnt/β-catenin signaling in prostate cancer.Solid Pseudopapillary Neoplasms of the Pancreas: A Surgical and Genetic Enigma.Dynein axonemal heavy chain 8 promotes androgen receptor activity and associates with prostate cancer progression.Evaluation of Hymenodictyon excelsum Phytochemical's Therapeutic Value Against Prostate Cancer by Molecular Docking Study.PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.Highlighting young investigators: guest editor Ramanuj DasGupta. Ram DasGupta: pushing the boundaries of β-catenin signaling and drug development.WNT signalling in prostate cancer.Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications.The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges.Resistance to Hormonal Therapy in Prostate Cancer.Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.Frequently rearranged and overexpressed δ-catenin is responsible for low sensitivity of prostate cancer cells to androgen receptor and β-catenin antagonists.Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer

P2860

Q28076060-9273605B-563F-427A-8913-EE28CDEDD7BA Q28277902-306150FC-0F37-4EA5-A19A-8575E7DA5B0F Q28546685-79D1D967-96FA-4B38-82E5-1D7BB44B7761 Q33917414-E21E8E60-32B3-4019-94F8-8A5092C99EE6 Q34365632-C1C8F382-34CF-46AA-ACD4-DD0C1069ACA2 Q34393633-D12D79B7-200E-4758-8FD7-BF96CDC586EB Q34550256-A3055CA8-F3EC-4189-805F-0ABFBF232246 Q35039889-DD862EAF-41F5-4315-B639-981AB54460DA Q35742116-500D1E36-0F14-4DBD-9BA2-99C6030CC5BC Q35762232-E59858C6-5354-4B19-B285-AE65CD88F7FB Q35823999-7ED50CDD-3094-4CA6-9D10-AC5471A1A6D7 Q36109796-358EB7C0-42B8-4DE1-8FFB-50DB2AAE9AAE Q36289531-598007DD-5CCF-4C92-9851-7F0CF671597D Q36316657-81B1EDAE-6948-4253-857E-FF9E2E8E0E20 Q37270422-4FC34A0B-50A9-40BB-A626-57EFF00B592E Q38241850-2D2C0414-3AB6-4224-AC97-E21730712B44 Q38668605-8EA27E66-9959-45AE-87C4-750B539135EB Q38780862-F1F5D7B3-9A6B-461E-9814-ECCFF3C2D339 Q39131794-6F08F128-5B41-4DBC-80C0-72DE1F662C98 Q39157381-017BAF7D-C0C3-4CC7-8F1F-C1593871B6E4 Q41263669-0A727430-1EA9-4DD2-85F0-C579A4B21756 Q42005437-7EFB040D-A190-4B3B-AA66-97378C0D2674 Q42938836-14A7A445-8A18-466A-9005-85C3D151ADAD Q45199839-A70CE5BD-9B7C-44B5-B0F2-F5C95EFCBAC4 Q47818549-CCEE3794-C29A-45E1-9B4A-DB5FEE3B380A Q49208785-AAAEEF5B-FC8E-4C8F-9FEB-16EF4F303F08 Q50889968-16651FD4-4321-4E22-B2EC-5F8E90A45259 Q53393993-9B1B7046-5882-45AF-9D67-FC7C0AC8F79C Q53481762-90F543E2-4C53-49CC-9D49-70385E53B404 Q54936285-59141908-2D9D-49CF-9E25-70131CA690FB Q57798889-C8DC7896-2FF6-4907-B663-1C2069757654

P2860

Inhibition of androgen receptor and β-catenin activity in prostate cancer

http://www.wikidata.org/entity/Q34982553

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@ast

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@en

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@nl

type

label

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@ast

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@en

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@nl

prefLabel

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@ast

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@en

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@nl

P1433

Q34982553-B00216ED-FE3D-4146-8D1E-6ACC585453D0

P1476

Q34982553-5FC8E3C9-0A63-49A2-9408-B721BF04C177

P2093

Q34982553-04125D5E-55C0-4374-B16E-A2679EBCD653

Q34982553-15B93984-E7DD-4D11-A7D5-1F2BB5ADCEC2

Q34982553-367C3180-6A57-4116-8B07-36F0140F571D

Q34982553-39244848-13ED-4266-BDE6-6237B9B1C4C3

Q34982553-82BD1859-0EFB-4B2D-A6DE-310E91C5F3FA

Q34982553-ECB64939-A4B0-4677-B7BD-28F1A312F5CA

P2860

Q34982553-0C3EC8A3-3170-475D-9A4E-571473232C06

Q34982553-11A8B10E-C2DB-40BA-A3BB-D58902EDD4CB

Q34982553-14685FDD-6E45-4502-B945-CEE51636DBDA

Q34982553-194BCF70-ECF2-4E91-B7FD-5E4544B5300B

Q34982553-252A3990-F0A4-466E-9922-FB6738711C31

Q34982553-34C5EE1B-CBBE-4B48-9B76-9C3E25FF3741

Q34982553-3504493F-A4C7-49C5-AA5D-35C746272CC8

Q34982553-3AE70243-B8D4-44EE-A04B-CD75F3DF939B

Q34982553-3B2295DC-2D56-4879-878D-AA5705EF6EF2

Q34982553-3BDC3DE6-0577-49C5-B0B8-0487A81275C8

P304

Q34982553-D9982DE7-8E71-4D28-9B4F-C23C11A07C26

P31

Q34982553-82BD6EBE-67C9-47A5-AA90-6562B29F5361

P356

Q34982553-69F6C0E8-D05F-4C82-98F3-76CCD56D8A4B

P407

Q34982553-E716FB1D-7F59-4DC7-A1A4-38089BB58228

P433

Q34982553-A27A511A-0040-404F-A1CA-45444F79CA96

P478

Q34982553-E8DA54B8-859E-4505-9265-15429D0CA44D

P577

Q34982553-A34F3E5D-8C99-4BAC-8DB5-52842A64D28C

P5875

Q34982553-1D63742D-7A7D-4DB7-A6E3-263A97FC9B3B

P698

Q34982553-1646F9C9-064B-4F03-B6BC-19FACDA147C9

P932

Q34982553-28C6D835-2FC4-42F4-98B8-73BF180938AE

P356

PNAS.1218168110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Inhibition of androgen receptor and β-catenin activity in prostate cancer

@en

P2093

Aviv Madar

http://www.w3.org/2001/XMLSchema#string

Eugine Lee

http://www.w3.org/2001/XMLSchema#string

Gregory David

http://www.w3.org/2001/XMLSchema#string

Michael J Garabedian

http://www.w3.org/2001/XMLSchema#string

Ramanuj Dasgupta

http://www.w3.org/2001/XMLSchema#string

Susan K Logan

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-catenin affects androgen receptor transcriptional activity and ligand specificity

A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4

LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation

Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Structural basis of coactivation of liver receptor homolog-1 by -catenin

The transcriptional coactivators p300 and CBP are histone acetyltransferases

Molecular determinants of resistance to antiandrogen therapy

P304

15710-15715

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1218168110

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256481596

http://www.w3.org/2001/XMLSchema#string

P698

24019458

http://www.w3.org/2001/XMLSchema#string

P932

3785716

http://www.w3.org/2001/XMLSchema#string